scholarly journals Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High Small Cell Lung Cancer: Results from the Phase 3 TAHOE Study

2021 ◽  
Author(s):  
Fiona Blackhall ◽  
Kevin Jao ◽  
Laurent Greillier ◽  
Byoung Chul Cho ◽  
Konstantin Penkov ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Second Line ◽  
Efficacy And Safety ◽  
Small Cell Lung ◽  
Second Line Therapy ◽  
Phase 3 ◽  
Line Therapy

Second-line therapy of squamous non-small cell lung cancer: an evolving landscape

2017 ◽  
Vol 11 (6) ◽  
pp. 469-479 ◽  
Author(s):  
Chiara Lazzari ◽  
Niki Karachaliou ◽  
Vanesa Gregorc ◽  
Alessandra Bulotta ◽  
Maria Gonzalez-Cao ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Second Line ◽  
Small Cell Lung ◽  
Second Line Therapy ◽  
Line Therapy

Second-Line Therapy for Non–Small-Cell Lung Cancer

2009 ◽  
Vol 10 (2) ◽  
pp. 91-98 ◽  
Author(s):  
Belisario A. Arango ◽  
Aurelio B. Castrellon ◽  
Edgardo S. Santos ◽  
Luis E. Raez
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Second Line ◽  
Small Cell Lung ◽  
Second Line Therapy ◽  
Line Therapy

scholarly journals Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients With Advanced Non–Small-Cell Lung Cancer: NCCTG and SWOG Study N0426

2010 ◽  
Vol 28 (4) ◽  
pp. 614-619 ◽  
Author(s):  
Alex A. Adjei ◽  
Sumithra J. Mandrekar ◽  
Grace K. Dy ◽  
Julian R. Molina ◽  
Araba A. Adjei ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Second Line ◽  
Small Cell Lung ◽  
Second Line Therapy ◽  
End Point ◽  
Line Therapy ◽  
Grade 3

Purpose To evaluate the efficacy and toxicity of pemetrexed combined with bevacizumab as second-line therapy for patients with advanced non–small-cell lung cancer (NSCLC) and to correlate allelic variants in pemetrexed-metabolizing genes with clinical outcome. Patients and Methods Patients with previously treated NSCLC received pemetrexed (500 mg/m2 intravenous) combined with bevacizumab (15 mg/kg intravenous) every 3 weeks. The primary end point, evaluated using a one-stage Fleming design for detecting a true success rate of at least 70%, was the proportion of patients who were progression free and on treatment at 3 months. Polymorphisms in genes responsible for pemetrexed transport (reduced folate carrier [SLC19A1]) and metabolism (folylpolyglutamate synthase [FPGS] and gamma-glutamyl hydrolase [GGH]) evaluated in germline DNA (blood) were correlated with treatment outcome. Results Forty-eight evaluable patients (14 females and 34 males) received a median of four cycles (range, one to 20 cycles). The most common grade 3 or 4 nonhematologic adverse events (AEs) were fatigue (13%), dyspnea (10%), and thrombosis (10%). Grade 3 or 4 hematologic AEs were neutropenia (19%) and lymphopenia (13%). Twenty-four (57%; 95% CI, 41% to 72%) of the first 42 patients met the success criteria. Median overall survival (OS) and progression-free survival (PFS) times were 8.6 and 4.0 months, respectively. The exon 6 (2522)C→T polymorphism in SLC19A1 correlated with 3-month progression-free status (P = .01) and with PFS (P = .05). The IVS1(1307)C→T polymorphism in GGH correlated with OS (P = .04). Conclusion The study did not meet its primary end point. However, the median PFS time of 4 months is promising. Pharmacogenetic studies in larger cohorts are needed to definitively identify polymorphisms that predict for survival and toxicity of pemetrexed.

scholarly journals A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer

2016 ◽  
Vol 48 (2) ◽  
pp. 465-472 ◽  
Author(s):  
Tak Yun ◽  
Heung Tae Kim ◽  
Ji-Youn Han ◽  
Sung Jin Yoon ◽  
Hyae Young Kim ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Phase Ii ◽  
Cell Lung Cancer ◽  
Phase Ii Study ◽  
Small Cell ◽  
Second Line ◽  
Small Cell Lung ◽  
Second Line Therapy ◽  
Line Therapy
Sign in / Sign up

Export Citation Format

Share Document